Kırıkkale ilinde küçük hücre dışı akciğer kanseri tanılı hastaların retrospektif değerlendirilmesi

Yıl 2018, Cilt: 10 Sayı: 2, 103 - 109, 01.09.2018

Selim Yalçın

https://doi.org/10.21601/ortadogutipdergisi.335600

Öz

Amaç:
Bu çalışmada kliniğimizde izlenen küçük hücre
dışı akciğer kanseri (KHDAK) hastalarının klinik ve epidemiyolojik
özellikleri, tedavileri, ortalama sağ kalımı,
sağ kalımı etkileyen faktörleri saptamayı amaçladık.

Gereç
ve Yöntem: Retrospektif
dizayndaki bu çalışmaya Kırıkkale Tıp Fakültesi İç Hastalıkları Anabilim
Dalı Tıbbi Onkoloji polikliniğine Ocak 2012-
Mayıs 2016 tarihleri arasında tanı ve tedavi
amacıyla başvuran 92  küçük hücre dışı akciğer kanseri
hastası dahil edildi.

Bulgular:
Hastaların 81’i erkek
(%88), 11’i kadın (%12), yaş ortalaması 65.3±8.99 idi (min:41, max:94).
Olguların %86,6 ’i aktif sigara içicisiydi.
Hastaların %94,5’inin başvuru
sırasında ECOG performans durumları 0 veya
1’di. Histolojik alt
gruplara göre hastaların 47
(%51,1)’i adenokarsinom,
39 (%42,4)’ü skuamöz hücreli
karsinom ve 6 (%6,5)’u diğer KHDAK’idi. Tümör tipleri ile lenfovasküler
invazyon varlığı karşılaştırıldığında adenokarsinomların %62,5’inde (n=5),
squamöz hücreli karsinomların %37,5’inde (n=3) lenfovasküler invazyonun olduğu
görülmüştür. Olguların %29,6’sında (n=8) lenfovasküler invazyon varken %70,4’ünde
(n=19) olmadığı görüldü. Lenfovasküler invazyon, ECOG performans durumu ve
kanser evresi sağ kalım üzerinde etkili bulunurken, yaş, cinsiyet,
komorbiditeler, sigara kullanımı, kanser tipi, kemoterapi ve beyin metastazları
sağ kalım üzerinde etkili değildi. Erkekler için ortanca sağ kalım 23,4 ay,
kadınlar için ise 18,1 aydı (p:0.633).

Sonuç:
Çalışmamızda kliniğimizde takip edilen küçük hücre dışı akciğer kanseri
hastalarının klinik, histolojik,  sağ
kalım özellikleri ve sağ kalım üzerinde etkili olan faktörler
değerlendirilmiştir.

Anahtar Kelimeler

Küçük hücre dışı, akciğer kanseri, sağ kalım, histolojik tip, ECOG

Retrospective evaluation of non-small cell lung cancer patients in Kırıkkale

Öz

Objective: 
In this study,
we aimed to determine the clinical
and  epidemiological features
of lung cancer patients, treatment modalities,  survival and factors affecting
survival in the patients who were followed up at our
clinic retrospectively.

Material and Method: Ninety two
non-small cell lung cancer patients
who were referred
to Kirikkale Faculty of
Medicine, Departmant of Medical Oncology Clinic between January 2012-May 2016
were included in the study.

Results: 
81 patients were male (88%) and 11 females (12%),that mean age was
65,3±8,99 years. 86.6% of the patients are actively smokers. At the time of diagnosis 94.5% of patients were
ECOG 0-1 performance status. For histopathologic subgroups, 47 (51.1%)
adenocarsinomo, 39 (42.4%) were squuamouscell carcinoma, 6 (6.5%) other NSCLC
subtypes. The
presence of lymphovascular invasion is compared with tumor types,
lymphovascular invasion have observed in 62.5% (n=5) of adenocarcinoma, 37.5%
(n=3) of squamous cell carcinoma. In the 29.6% (n=8) of the cases, there was
lymphovascular invasion but the lymphovascular invasion have not observed in
the majority of the patients (%70.4, n=19). Median
survival was 23.4 months in males, 18.1 months in women (p= 0.63). The
survival was effected by lymphovascular invasion, ECOG performance status and
cancer stage but not by age, sex, co-morbidity, smoking, cancer type, treating
with chemotherapy, existing brain metastasis.

Conclusions: In conclusion, our study evaluates clinical, histologic, survival
features and factors affecting survival
in non-small cell lung cancer patients who were followed up at
our clinic.

 

Anahtar Kelimeler

Non-small cell, lung cancer, survival, histologic subtypes, ECOG

Kaynakça

• 1. Spiro SG, Porter JC Lung cancer – Where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 166: 1166–1196,2002. 2. Jemal A, Bray F et al. "Global cancer statistics." CA Cancer J Clin 61(2): 69-90,2011. 3. Nacht M, Dracheva T, Gao Y, et al. Molecular characteristics of non-small cell lung cancer. ProcNatl Acad Sci U S A. 2001; 98: 15203-8. 4. Novaes FT, Cataneo DC. Lung cancer: histology, staging, treatment and survival. J Bras Pneumol 2008; 34: 595-600. 5. Cappuzzo F, Ligorio C, Toschi L, et al. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 2: 423-9. 6. Tu H, Heymach JV, Wen C-P, et al. Different dietary patterns and reduction of lung cancer risk: A large case-control study in the U.S. Scientific Reports. 2016;6:26760. doi:10.1038/srep26760. 7. Chen J, Li W, Cui L, et al. Chemotherapeutic Response and Prognosis among Lung Cancer Patients with and without Depression. Journal of Cancer. 2015;6(11):1121-1129. doi:10.7150/jca.11239. 8. Yin J, Li Y, Zhao H, et al. Copy‐number variation of MCL1 predicts overall survival of non‐small‐cell lung cancer in a Southern Chinese population. Cancer Medicine. May 2016:10.1002/cam4.774. doi:10.1002/cam4.774. 9. Lis CG, Patel K, Gupta D. The Relationship between Patient Satisfaction with Service Quality and Survival in Non-Small Cell Lung Cancer – Is Self-Rated Health a Potential Confounder? de Mello RA, ed. PLoS ONE. 2015;10(7):e0134617. 10. Chaari A, Ben Nasr S, Labidi S, Afrit M, Boussen H. Metastatic non-small cell lung cancer: a Tunisian retrospective study about 100 cases. Tunis Med. 2015 May;93(5):294-6. 11. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011;8(6):344–56. Epub 2011/04/14. 12. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21(13):2529–36. Epub 2003/06/28. 13. Tigin C, Kıyık M, Çıkrıkçıoğlu S, et al. The role of computed tomography in the detection of brain metastasis in non-small cell lung cancer. Medical bulletin of Heybeliada 2003; 9:16-8. 14. Li BT, Lou E, Hsu M, et al. Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. Dutt A, ed. PLoS ONE. 2016;11(1):e0146063. doi:10.1371/journal.pone.0146063. 15. Özgül A,Uysal A, Kadakal F,Altoparlak B, Cinemre H, Yılmaz V. Küçük hücreli dışı akciğer kanseri beyin metastazı tanısında bilgisayarlı beyin tomografisi ve manyetik rezonans görüntüleme yönteminin karşılaştırılması. Tüberküloz ve Toraks Dergisi.2006,54(3. 16. Wisnivesky JP, Yankelevitz D, Henschke CI. Stage of lung cancer in relation to its size: part 2. Evidence. Chest. 2005;127(4):1136–1139. 17. Nakayama H, Satoh H, Kurishima K, Ishikawa H. Tokuuye K. High-dose conformal radiotherapy for patients with stage III non-small-cell lung carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2010;78:645–650. 18. Rades D, Setter C, Dahl O, Schild SE. Noack F. Prognostic impact of erythropoietin expression and erythropoietin receptor expression on locoregional control and survival of patients irradiated for stage II/III non-small-cell lung cancer. Int. J. Radiat. . Oncol. Biol. Phys. 2011;80:499–505. 19. Shen G, Bian G, Yu H, Gao M, Kang D, Hu S. Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. Mol Clin Oncol. 2014;2:146–50. 20. Owonikoko TK, Ragin C, Chen Z, Kim S, Behera M, Brandes JC, Saba NF, Pentz R, Ramalingam SS, Khuri FR. Real-world effectiveness of systemic agents approved for advanced nonsmall cell lung cancer: a SEER-Medicare analysis. Oncologist. 2013;18:600–610. 21. Shen G, Bian G, Yu H, Gao M, Kang D, Hu S. Comparison between cisplatin plus vinorelbine and cisplatin plus docetaxel in the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. Mol Clin Oncol. 2014;2:146–50. 22. Ahn MJ, Lee J, Park YH et al. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine . kinase inhibitor era. J Thorac Oncol 2010;5:1185–9